SNCB and Alzheimer disease: Furthermore, we investigated the GAP43/PTPRN2 and SNCB/PTPRN2 ratios in the full discovery cohort (n= 213) with respect to the clinical diagnosis of patients, including both AD and MCI patients in the A-T- group (total n= 148).